Skip to search formSkip to main contentSkip to account menu

TP-0903

Known as: AXL Inhibitor TP-0903, TP 0903, TP0903 
An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Broader (2)

PyrimidinesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase.
2020
2020
Abstract P6-03-05: AXL-HER2 dimer as mechanism of anti-HER2 acquired resistance in HER2 amplified brest cancer models: A new step towards precision medicine
Background: Breast cancer (BC) is a heterogeneous disease. HER2+ BC represents between 15-20% of cases. Trastuzumab, a monoclonal… 
2019
2019
Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma.
AIMS To investigate the functions and underlying mechanisms of AXL receptor tyrosine kinase (AXL) in tumor proliferation and… 
2018
2018
A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to…
TPS2612Background: AXL kinase has emerged as a key regulator of the epithelial to mesenchymal transition (EMT), a process that… 
2018
2018
Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
2018
2018
Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug…
Introduction CLL remains an incurable disease and represents a significant health problem in the western world. Increasing… 
2017
2017
Abstract 298: WEE1 inhibitor activity correlates to AXL/mTOR expression and exhibits synergy with temozolomide (TMZ) in small cell lung cancer (SCLC)
Background: WEE1 inhibitors (WEEi) are a novel class of small molecule inhibitors that are now under early clinical trials for… 
2015
2015
Abstract 4096: Identification of EMT inhibitors using novel zebrafish reporter lines
The Epithelial to Mesenchymal Transition (EMT) plays a crucial role during development and aberrant reactivation of EMT in tumor… 
2014
2014
Inhibition of PIM and AXL Kinases As Potential Treatments for a Variety of Hematological Malignancies and Solid Tumors
Inhibition of PIM and AXL Kinases as Potential Treatments for a Variety of Hematological Malignancies and Solid Tumors Kent J… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)